Dr Patricia Jaaks | Postdoctoral Fellow

Jaaks, Patricia

Within the Translational Cancer Genomics group, Patricia works on large-scale combination drug screens in cancer cell lines to establish a combination drug screen analysis framework and to identify novel cancer therapies and genetic biomarkers of synergy.

Publications

  • The Proprotein Convertase Furin in Tumour Progression.

    Jaaks P and Bernasconi M

    International journal of cancer 2017

  • The proprotein convertase furin is required to maintain viability of alveolar rhabdomyosarcoma cells.

    Jaaks P, Meier G, Alijaj N, Brack E, Bode P et al.

    Oncotarget 2016;7;47;76743-76755

  • Targeting hedgehog signaling reduces self-renewal in embryonal rhabdomyosarcoma.

    Satheesha S, Manzella G, Bovay A, Casanova EA, Bode PK et al.

    Oncogene 2016;35;16;2020-30

  • The Proprotein Convertase Furin Contributes to Rhabdomyosarcoma Malignancy by Promoting Vascularization, Migration and Invasion.

    Jaaks P, D'Alessandro V, Grob N, Büel S, Hajdin K et al.

    PloS one 2016;11;8;e0161396

  • The catalytic domain of inositol-1,4,5-trisphosphate 3-kinase-a contributes to ITPKA-induced modulation of F-actin.

    Ashour DJ, Pelka B, Jaaks P, Wundenberg T, Blechner C et al.

    Cytoskeleton (Hoboken, N.J.) 2015;72;2;93-100

Jaaks, Patricia
Patricia's Timeline
2016

Postdoctoral Fellow at the Wellcome Trust Sanger Institute

Awarded PhD from University of Zurich, Switzerland PhD project: 'The proprotein convertase furin is a key regulator of paediatric sarcoma malignancy', University Children's Hospital Zurich

2011

Graduated from Imperial College London, UK, MSc Molecular Medicine

2010

Graduated from University of Hamburg, Germany, BSc Molecular Life Sciences